Screener
MeiraGTx Holdings plc MGTX Q2 2026 earnings
Reported August 13, 2026 · Before market open
Revenue$321.4MBeat by $320.7M
EPS$1.71Beat by $2.17
Revenue estimate$700.0K
EPS estimate-$0.46
“We acquired bota-vec from J&J and started working on the global filings for this product and establishing the market access and commercial infrastructure ahead of the potential first commercial launch in 2027. In addition, we made meaningful progress with our wholly owned AAV2-hAQP1 program for a significant unmet need, radiation induced xerostomia (RIX). We were awarded Breakthrough Therapy Designation in March 2026 based on very strong 3-year data from our Phase 1 AQUAx clinical study (n=24), indicating strong durable responses in late-stage RIX patients. We completed enrollment in our pivotal Phase 2 AQUAx2 clinical study of AAV2-hAQP1 in RIX in the second quarter and are now working expeditiously to submit regulatory filings for bota-vec this year and preparing for AAV2-hAQP1 filings mid next year.”
Next report
Nov 12, 2026 (in 2 months)Revenue estimate$7.1M
EPS estimate-$0.46
Valuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did MeiraGTx Holdings plc report Q2 2026 earnings?
- MeiraGTx Holdings plc (MGTX) reported Q2 2026 earnings on August 13, 2026 before market open.
- What were MeiraGTx Holdings plc's Q2 2026 revenue and EPS?
- MeiraGTx Holdings plc reported revenue of $321.4M and eps of $1.71 for Q2 2026.
- Did MeiraGTx Holdings plc beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $700.0K by $320.7M. EPS beat the consensus estimate of $-0.46 by $2.17.
- How did MeiraGTx Holdings plc's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 8608.6% from $3.7M a year earlier.
- Where can I find MeiraGTx Holdings plc's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-095491) and the 10-Q periodic report (0001104659-26-095504) directly on SEC EDGAR. The filing index links above go to sec.gov.
